Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

853 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is rectal administration an alternative route for imatinib?
van Erp NP, Oostendorp RL, Guchelaar HJ, Schellens JH, Gelderblom H. van Erp NP, et al. Among authors: gelderblom h. Cancer Chemother Pharmacol. 2007 Sep;60(4):623-4. doi: 10.1007/s00280-006-0409-0. Epub 2007 Feb 8. Cancer Chemother Pharmacol. 2007. PMID: 17287936 Free article. No abstract available.
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
van Erp NP, Gelderblom H, Karlsson MO, Li J, Zhao M, Ouwerkerk J, Nortier JW, Guchelaar HJ, Baker SD, Sparreboom A. van Erp NP, et al. Among authors: gelderblom h. Clin Cancer Res. 2007 Dec 15;13(24):7394-400. doi: 10.1158/1078-0432.CCR-07-0346. Clin Cancer Res. 2007. PMID: 18094422 Clinical Trial.
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H. Eskens FA, et al. Among authors: gelderblom h. J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636022 Clinical Trial.
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
Steeghs N, Eskens FA, Gelderblom H, Verweij J, Nortier JW, Ouwerkerk J, van Noort C, Mariani M, Spinelli R, Carpinelli P, Laffranchi B, de Jonge MJ. Steeghs N, et al. Among authors: gelderblom h. J Clin Oncol. 2009 Oct 20;27(30):5094-101. doi: 10.1200/JCO.2008.21.6655. Epub 2009 Sep 21. J Clin Oncol. 2009. PMID: 19770380 Clinical Trial.
853 results